MCID: TBR010
MIFTS: 69

Tuberculosis

Categories: Rare diseases, Infectious diseases, Reproductive diseases, Respiratory diseases, Endocrine diseases

Aliases & Classifications for Tuberculosis

MalaCards integrated aliases for Tuberculosis:

Name: Tuberculosis 12 50 56 52 41 3 3 3 42 14 69
Tb 50 45 3
Tuberculoma 42 69
Tuberculosis, Susceptibility to 13
Kochs Disease 50

Classifications:



External Ids:

Disease Ontology 12 DOID:399
SNOMED-CT 64 15202009
Orphanet 56 ORPHA3389
MESH via Orphanet 43 D014376
UMLS via Orphanet 70 C0041296
ICD10 33 A15-A19 A17.9
UMLS 69 C0041295

Summaries for Tuberculosis

MedlinePlus : 41 tuberculosis (tb) is a disease caused by bacteria called mycobacterium tuberculosis. the bacteria usually attack the lungs, but they can also damage other parts of the body. tb spreads through the air when a person with tb of the lungs or throat coughs, sneezes, or talks. if you have been exposed, you should go to your doctor for tests. you are more likely to get tb if you have a weak immune system. symptoms of tb in the lungs may include a bad cough that lasts 3 weeks or longer weight loss loss of appetite coughing up blood or mucus weakness or fatigue fever night sweats skin tests, blood tests, x-rays, and other tests can tell if you have tb. if not treated properly, tb can be deadly. you can usually cure active tb by taking several medicines for a long period of time. nih: national institute of allergy and infectious diseases

MalaCards based summary : Tuberculosis, also known as tb, is related to pulmonary tuberculosis and mycobacterium kansasii, and has symptoms including weight loss, fever and abnormality of lung morphology. An important gene associated with Tuberculosis is SLC11A1 (Solute Carrier Family 11 Member 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Priftin and Sirturo have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and hematopoietic system

NIH Rare Diseases : 50 tuberculosis (tb) is a contagious and often severe airborne disease caused by the tb bacterium, mycobacterium tuberculosis. tb typically affects the lungs, but other organs of the body may be involved, as well. not everyone who is infected with the tb bacterium becomes sick. tb bacterial infections only become "active disease" if the immune system can't stop them from growing. classic signs and symptoms of active tb can include cough, weight loss, fever, night sweats, hemoptysis, chest pain, and fatigue. symptoms involving areas of the body other than the lungs vary depending on which organ(s) are affected. tb is usually treated with a regimen of medications taken over a long period of time (often six to twelve months). last updated: 2/4/2016

Disease Ontology : 12 A primary bacterial infectious disease that is located in lungs, located in lymph nodes, located in pericardium, located in brain, located in pleura or located in gastrointestinal tract, has material basis in Mycobacterium tuberculosis, which is transmitted_by droplets released into the air when an infected person coughs or sneezes.

Wikipedia : 72 Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis (MTB).... more...

Related Diseases for Tuberculosis

Diseases related to Tuberculosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 915)
id Related Disease Score Top Affiliating Genes
1 pulmonary tuberculosis 34.7 CD209 IFNG STAT1 TNF
2 mycobacterium kansasii 32.9 IFNGR2 TLR2 TNF
3 melioidosis 32.6 IFNG IL10 TLR2 TLR4 TNF
4 dysphagia 31.0 IFNG IL10 TNF
5 hemophagocytic lymphohistiocytosis 30.9 IFNG IL10 TNF
6 choroiditis 30.9 IL10 IL1B TLR4 TNF
7 lymphoma 30.9 IFNG IL10 IL1B TLR9 TNF
8 pyelonephritis 30.7 IL10 IL1B TNF
9 aseptic meningitis 30.4 TLR2 TLR4 TNF
10 nasopharyngitis 30.4 TLR2 TLR4 TNF
11 tularemia 30.2 IFNG IL10 TLR9 TNF
12 epidermolysis bullosa acquisita 30.2 IFNG IL10 STAT1
13 membranoproliferative glomerulonephritis 30.1 IFNG TLR9 TNF
14 asthma 29.9 IFNG IL10 IL1B TLR6 TLR9 TNF
15 pulmonary embolism 29.8 IFNG IL10 IL1B TLR2 TLR9 TNF
16 steatorrhea 29.8 B2M IFNG TNF
17 hepatitis b 29.8 B2M GNLY IFNG IL10 TNF
18 rift valley fever 29.7 IFNG IFNGR1 IL1B SLC11A1 TLR4 TNF
19 hypervitaminosis d 29.6 IFNG IL10 IL1B TLR2 TLR9 TNF
20 esophageal candidiasis 29.6 IFNG IL10 TNF
21 rheumatoid arthritis 29.5 IFNG IL10 IL1B MIF SLC11A1 TLR2
22 primary biliary cirrhosis 29.4 B2M IL10 SLC11A1 TNF
23 calcinosis 29.2 B2M TLR9 TNF
24 acral lentiginous melanoma 29.2 B2M IFNG IL10 IL1B TNF
25 atherosclerosis 29.2 IFNG IL10 IL1B MIF TNF
26 scabies 29.1 B2M IFNG IL10 IL1B TLR2 TNF
27 kaposi sarcoma 28.8 HSPD1 IL1B MIF SLC11A1 TNF
28 malaria 28.0 IFNG IFNGR1 IL10 IL12B IL1B MIF
29 miliary tuberculosis 12.3
30 gastrointestinal tuberculosis 12.2
31 urogenital tuberculosis 12.2
32 pleural tuberculosis 12.2
33 skeletal tuberculosis 12.2
34 multidrug-resistant tuberculosis 12.2
35 laryngeal tuberculosis 12.2
36 lymph node tuberculosis 12.2
37 renal tuberculosis 12.1
38 hepatic tuberculosis 12.1
39 extrapulmonary tuberculosis 12.1
40 intestinal tuberculosis 12.1
41 bladder tuberculosis 12.1
42 abdominal tuberculosis 12.1
43 central nervous system tuberculosis 12.1
44 esophageal tuberculosis 12.1
45 splenic tuberculosis 12.1
46 oral tuberculosis 12.1
47 pericardial tuberculosis 12.0
48 ureter tuberculosis 11.9
49 cardiac tuberculosis 11.9
50 mycobacterium tuberculosis 3 11.8

Graphical network of the top 20 diseases related to Tuberculosis:



Diseases related to Tuberculosis

Symptoms & Phenotypes for Tuberculosis

Human phenotypes related to Tuberculosis:

56 32
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 weight loss 56 32 frequent (33%) Frequent (79-30%) HP:0001824
2 fever 56 32 frequent (33%) Frequent (79-30%) HP:0001945
3 abnormality of lung morphology 56 32 frequent (33%) Frequent (79-30%) HP:0002088
4 fatigue 56 32 frequent (33%) Frequent (79-30%) HP:0012378
5 cough 56 32 frequent (33%) Frequent (79-30%) HP:0012735

UMLS symptoms related to Tuberculosis:


coughing, fever, pruritus, snoring

GenomeRNAi Phenotypes related to Tuberculosis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.98 IL10 CD209 IL1B HSPD1 MIF
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.98 IL1B
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.98 CD209
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.98 IL10
5 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.98 IL10
6 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.98 HSPD1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.98 IL10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.98 IL10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.98 HSPD1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.98 CD209 MIF
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.98 IL10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.98 MIF
13 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.98 IL10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.98 HSPD1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.98 IL1B
16 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.98 IL1B
17 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.98 CD209
18 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.98 IL10 IL1B
19 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.98 IL1B
20 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.98 IL10
21 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.98 MIF IL10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.98 CD209
23 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.98 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.98 CD209
25 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.98 CD209
26 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.98 CD209 IL1B
27 Increased shRNA abundance (Z-score > 2) GR00366-A-51 9.98 IL1B
28 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.98 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.98 HSPD1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.98 IL10
31 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.98 IL1B
32 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.98 IL10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.98 CD209 IL1B
34 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.98 IL10
35 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.98 IL10
36 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.98 HSPD1

MGI Mouse Phenotypes related to Tuberculosis:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.42 B2M IFNG IFNGR1 IFNGR2 IL10 IL12B
2 immune system MP:0005387 10.39 B2M IFNG IFNGR1 IFNGR2 IL10 IL12B
3 homeostasis/metabolism MP:0005376 10.35 B2M IFNG IFNGR1 IFNGR2 IL10 IL12B
4 cellular MP:0005384 10.3 HSPD1 IFNG IFNGR1 IL10 MIF STAT1
5 digestive/alimentary MP:0005381 10.29 TNF VDR IFNGR1 IL10 IL12B SLC11A1
6 cardiovascular system MP:0005385 10.28 STAT1 TIRAP TLR2 TLR4 TNF VDR
7 mortality/aging MP:0010768 10.24 HSPD1 IFNG IFNGR1 IL10 IL12B IL1B
8 integument MP:0010771 10.13 B2M IFNG IFNGR1 IL10 IL1B STAT1
9 neoplasm MP:0002006 10.03 IFNGR1 IL10 IL12B IL1B MIF SLC11A1
10 liver/biliary system MP:0005370 10.01 B2M IFNG IFNGR1 IL10 STAT1 TLR2
11 nervous system MP:0003631 9.93 IFNGR1 IL10 IL1B MIF STAT1 TLR2
12 muscle MP:0005369 9.92 HSPD1 IFNG IL10 STAT1 TLR2 TLR4
13 reproductive system MP:0005389 9.61 HSPD1 IFNG IFNGR1 IL10 TLR4 TLR6
14 skeleton MP:0005390 9.32 IFNG IFNGR1 IL10 IL12B IL1B STAT1

Drugs & Therapeutics for Tuberculosis

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Priftin 17 RIFAPENTINE Hoechst Marion Roussel June 1998
2
Sirturo 17 BEDAQUILINE FUMARATE Janssen Therapeutics December 2012

Drugs for Tuberculosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 488)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethambutol Approved Phase 4,Phase 3,Phase 2,Phase 1 74-55-5 3279 14052
2
Isoniazid Approved Phase 4,Phase 3,Phase 2,Phase 1 54-85-3 3767
3
Pyrazinamide Approved Phase 4,Phase 3,Phase 2,Phase 1 98-96-4 1046
4
Rifampin Approved Phase 4,Phase 3,Phase 2,Phase 1 13292-46-1 5458213 5381226
5
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757
6
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1 57-63-6 5991
7
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 354812-41-2, 151096-09-2 152946
8
Norgestimate Approved Phase 4,Phase 3,Phase 2,Phase 1 35189-28-7 6540478
9
Rifabutin Approved Phase 4,Phase 2,Phase 3,Phase 1 72559-06-9 6323490
10
Streptomycin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 57-92-1 19649
11
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
12
Abacavir Approved, Investigational Phase 4,Phase 3 136470-78-5 65140 441300
13
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
14
Artemether Approved Phase 4 71963-77-4 119380 68911
15
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154598-52-4 64139
16
Lumefantrine Approved Phase 4 82186-77-4 6437380
17
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
18
Nevirapine Approved Phase 4,Phase 3,Phase 2,Phase 1 129618-40-2 4463
19
Zidovudine Approved Phase 4,Phase 3,Phase 1 30516-87-1 35370
20
Clarithromycin Approved Phase 4,Phase 3 81103-11-9 84029
21
Linezolid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 165800-03-3 441401
22
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 143491-57-0 60877
23
Nelfinavir Approved Phase 4,Phase 1 159989-64-7 64143
24
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100986-85-4 149096
25
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1 82419-36-1 4583
26
Stavudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3056-17-5 18283
27
Lopinavir Approved Phase 4,Phase 2,Phase 1 192725-17-0 92727
28
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 1 155213-67-5 392622
29
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2 216974-75-3
30
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 2 723-46-6 5329
31
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 2 738-70-5 5578
32
Amikacin Approved, Vet_approved Phase 4,Phase 3,Phase 2 37517-28-5 37768
33
Capreomycin Approved Phase 4,Phase 3 11003-38-6 3000502
34
Clofazimine Approved, Investigational Phase 4,Phase 3,Phase 2 2030-63-9 2794
35
Cycloserine Approved Phase 4,Phase 2,Phase 3,Phase 1 68-41-7 401 6234
36
Gatifloxacin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 112811-59-3 5379
37
Rifapentine Approved Phase 4,Phase 3,Phase 2,Phase 1 61379-65-5 6323497
38
Calcium Carbonate Approved Phase 4,Phase 3 471-34-1
39
Bedaquiline Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 843663-66-1
40
Dapsone Approved, Investigational Phase 4 80-08-0 2955
41
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
42
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
43
Etanercept Approved, Investigational Phase 4 185243-69-0
44
Methotrexate Approved Phase 4,Phase 3 1959-05-2, 59-05-2 126941
45
Ustekinumab Approved, Investigational Phase 4,Phase 2 815610-63-0
46
Aminosalicylic Acid Approved Phase 4,Phase 2,Phase 3,Phase 1 65-49-6 4649
47
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 1 26787-78-0 33613 2171
48
Azithromycin Approved Phase 4,Phase 2 83905-01-5 55185 53477736 447043
49
Ethionamide Approved Phase 4,Phase 2,Phase 3 536-33-4 2761171
50
Kanamycin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 8063-07-8, 59-01-8 6032

Interventional clinical trials:

(show top 50) (show all 1063)

id Name Status NCT ID Phase Drugs
1 Can Screening People Registering With Primary Care Improve the Detection of Tuberculosis? Unknown status NCT00214708 Phase 4
2 Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216333 Phase 4 combined fixed dose combination
3 Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes Unknown status NCT01782950 Phase 4 Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
4 Randomized Controlled Trial of Percutaneous and Intradermal BCG Vaccination. Unknown status NCT00242047 Phase 4
5 Research on New Regimens for Retreatment Pulmonary Tuberculosis Unknown status NCT02331823 Phase 4 Isoniazid Aminosalicylate Tablets;Streptomycin injectable
6 Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults Unknown status NCT01811823 Phase 4
7 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
8 Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis Unknown status NCT02464683 Phase 4
9 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
10 Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL) Unknown status NCT01875952 Phase 4 Isoniazid
11 Interferon-Gamma Release Assays in Tuberculosis (TB) - HIV Co-infected Children Unknown status NCT00604617 Phase 4 RT-23
12 Use TST and QFT-RD1 Test to Monitor the Tuberculous Infection in Patients, Close Contact People and Health Care Workers Unknown status NCT00311220 Phase 4 tuberculin for skin test
13 Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
14 Epidemiology of MDR-TB in Peru Unknown status NCT00676754 Phase 4
15 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis Unknown status NCT01223976 Phase 4
16 Simple Verbal Intervention for Adequately Collecting Sputum Unknown status NCT01135043 Phase 4
17 Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
18 NAT2 in Re-challenge of INH in Patients With Hepatitis Unknown status NCT00728546 Phase 4 Isoniazid (Rifinah)
19 Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion Unknown status NCT00313066 Phase 4
20 A Randomized Trial of Providing BCG Vaccination Immediately Unknown status NCT01989026 Phase 4
21 Quantiferon for Detection of Latent Tuberculosis in Healthcare Workers Completed NCT00797836 Phase 4
22 Improving Community Based Tuberculosis Care in Ethiopia Completed NCT00803322 Phase 4
23 The Effectiveness of Health Facility-based and Community-based Care for Tuberculosis Completed NCT00939419 Phase 4
24 Treatment of Latent Tuberculosis Infection With Isoniazid Completed NCT00293228 Phase 4 Isoniazid;isoniazid
25 QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study. Completed NCT01223534 Phase 4 Preventive treatment with Isoniazid.;Preventive treatment with Isoniazid
26 Tuberculosis and Human Immunodeficiency Virus (HIV) Immune Reconstitution Syndrome Trial (THIRST) Completed NCT00851630 Phase 4 Fixed dose combination zidovudine/lamivudine/abacavir
27 A Randomized Trial of Three Regimens to Prevent Tuberculosis in HIV-Infected Patients With Anergy Completed NCT00402610 Phase 4 isoniazid, rifampin + isoniazid, rifampin + pyrazinamide or not treatment
28 Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana Completed NCT00164281 Phase 4 Isoniazid
29 Investigation of a Novel Approach to Improve Treatment Success Rates for Tuberculosis Patients in Senegal Completed NCT00412009 Phase 4
30 Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients Completed NCT01521364 Phase 4 Addition of different doses of clarithromycin.
31 Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil Completed NCT01363765 Phase 4
32 Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis Completed NCT00108862 Phase 4
33 Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT Completed NCT00647205 Phase 4
34 TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB Completed NCT00023400 Phase 4 Nelfinavir;Rifabutin
35 Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT) Completed NCT00298870 Phase 4 Isoniazid;isoniazed
36 Wirelessly Observed Therapy in Comparison to Directly Observed Therapy for the Treatment of Tuberculosis Completed NCT01960257 Phase 4
37 Evaluation of Three Regimens of Chemoprophylaxis for Tuberculosis in Patients co-Infected by HIV and Mycobacterium Tuberculosis Completed NCT00402454 Phase 4 isoniazid, rifampin + isoniazid or rifampin + pyrazinamide
38 Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya Completed NCT00850915 Phase 4
39 MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis Completed NCT00495339 Phase 4 Levofloxacin
40 Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis Completed NCT00617643 Phase 4 Nevirapine without dose escalation;Nevirapine initiation with dose escalation
41 TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy) Completed NCT00107887 Phase 4 INH preventive therapy;TST (tuberculin skin test)
42 Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women Completed NCT01494038 Phase 4 Isoniazid (INH);Placebo for isoniazid (INH)
43 An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin Completed NCT00771498 Phase 4 Lopinavir
44 Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing in Patients With Chronic Liver Disease Completed NCT00402402 Phase 4
45 REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment Completed NCT01380080 Phase 4 Atripla (r);Efavirenz;Truvada;Rifampin/isoniazid/pyrazinamide/ethambutol FDC;Rifampin/isoniazid FDC;Isoniazid
46 Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB Completed NCT02348177 Phase 4 lopinavir with ritonavir in 1:1 ratio;Lopinavir/ritonavir 4:1
47 Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage Completed NCT00405301 Phase 4 Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)
48 Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study) Completed NCT01637558 Phase 4 8 hourly LPV/r during TB treatment;Nevirapine;Lopinavir/Ritonavir
49 Should Low Birth Weight Infants Be Vaccinated With BCG Vaccine at Birth in Developing Countries? Completed NCT00146302 Phase 4
50 Effect of Weight and/or Obesity on Ethambutol Drug Concentrations Completed NCT01048697 Phase 4 Ethambutol

Search NIH Clinical Center for Tuberculosis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: tuberculosis

Genetic Tests for Tuberculosis

Anatomical Context for Tuberculosis

MalaCards organs/tissues related to Tuberculosis:

39
Testes, Lung, T Cells, Skin, Lymph Node, Liver, Monocytes

Publications for Tuberculosis

Articles related to Tuberculosis:

(show top 50) (show all 8536)
id Title Authors Year
1
[Miliary tuberculosis: the role of necropsy studies]. ( 28603236 )
2017
2
Urogenital Tuberculosis. ( 28087922 )
2017
3
A benign cause of Sister Mary Joseph's nodule: Abdominal tuberculosis. ( 28776536 )
2017
4
Invasive mucinous adenocarcinoma with lepidic-predominant pattern coexisted with tuberculosis: a case report. ( 28687977 )
2017
5
Tuberculosis masked by immunodeficiency: a review of two cases diagnosed with chronic granulomatous disease. ( 28621249 )
2017
6
Treatment outcome of extrapulmonary tuberculosis under Revised National Tuberculosis Control Programme. ( 28410692 )
2017
7
Pulmonary sarcoidosis mimicking tuberculosis: Importance of the galaxy sign on thoracic computed tomography. ( 28863878 )
2017
8
Epidemiology of Nontuberculous Mycobacterial Lung Disease and Tuberculosis, Hawaii, USA. ( 28221128 )
2017
9
Endosonographic features of esophageal tuberculosis presenting as a subepithelial lesion. ( 28139030 )
2017
10
Nitric oxide in cerebrospinal fluid of central nervous system tuberculosis: correlations with culture, antibody response, and cell count. ( 28263476 )
2017
11
Complex regulation of neutrophil-derived MMP-9 secretion in central nervous system tuberculosis. ( 28173836 )
2017
12
Addison's Disease Caused by Tuberculosis with Atypical Hyperpigmentation and Active Pulmonary Tuberculosis. ( 28717080 )
2017
13
Evaluation of the XpertAr MTB/RIF assay and microscopy for the diagnosis of Mycobacterium tuberculosis in Namibia. ( 28086955 )
2017
14
Discovery of Novel Inhibitors of Mycobacterium tuberculosis MurG: Homology Modelling, Structure Based Pharmacophore, Molecular Docking, and Molecular Dynamics Simulations. ( 28948866 )
2017
15
Secretion of IFN-I^ Associated with Galectin-9 Production by Pleural Fluid Cells from a Patient with Extrapulmonary Tuberculosis. ( 28657598 )
2017
16
Intestinal tuberculosis: a diagnostic challenge. ( 28609809 )
2017
17
Multiple jejunal perforation secondary to intestinal tuberculosis infection: a case report. ( 28819499 )
2017
18
Prevention of hearing loss in patients with multidrug-resistant tuberculosis. ( 28872029 )
2017
19
Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis. ( 28089216 )
2017
20
Myeloid and T Cell-Derived TNF Protects against Central Nervous System Tuberculosis. ( 28280495 )
2017
21
High Detection Rates of Urine Mycobacterium tuberculosis in Patients with Suspected Miliary Tuberculosis. ( 28420836 )
2017
22
Endoscopic ultrasound in diagnosis of esophageal tuberculosis: 10-year experience at a tertiary care center. ( 28575247 )
2017
23
Association study of the FTO gene polymorphisms with the risk of pulmonary tuberculosis in a sample of Iranian population. ( 28357924 )
2017
24
The impact of ISGylation during Mycobacterium tuberculosis infection in mice. ( 28087453 )
2017
25
Meta-Analytic Bayesian Model For Differentiating Intestinal Tuberculosis from Crohn's Disease. ( 28045023 )
2017
26
Gross Hematuria Is More Common in Male and Older Patients with Renal Tuberculosis in China: A Single-Center 15-Year Clinical Experience. ( 28343213 )
2017
27
Miliary tuberculosis during adalimumab therapy in Crohn's disease. ( 28743405 )
2017
28
Toll-like receptor-2 Arg753Gln and Arg677Trp polymorphisms and susceptibility to pulmonary and peritoneal tuberculosis. ( 28332241 )
2017
29
Is it intestinal tuberculosis again? Case report. ( 28726436 )
2017
30
Tuberculosis mimicking primary systemic vasculitis: not to be missed! ( 28092221 )
2017
31
BTLA-expressing CD11c antigen presenting cells in patients with active tuberculosis exhibit low capacity to stimulate T cell proliferation. ( 27717503 )
2017
32
A mathematical model predicting host mitochondrial pyruvate transporter activity to be a critical regulator of Mycobacterium tuberculosis pathogenicity. ( 28263840 )
2017
33
Tissue inhibitor of metalloproteinases 1, a novel biomarker of tuberculosis. ( 27959391 )
2017
34
Multidetector CT urography in urogenital tuberculosis: use of reformatted images for the assessment of the radiological findings. A pictorial essay. ( 28389790 )
2017
35
Clinical usefulness of (18)F-FDG PET/CT for initial staging and assessment of treatment efficacy in patients with lymph node tuberculosis. ( 28426991 )
2017
36
Isolated splenic tuberculosis diagnosed by endoscopic ultrasound-guided fine needle aspiration. ( 28410696 )
2017
37
Pleural Tuberculosis following Infliximab Therapy for Ankylosing Spondylitis. ( 28405137 )
2017
38
Serum amyloid A, protein Z, and C4b-binding protein I^ chain as new potential biomarkers for pulmonary tuberculosis. ( 28278182 )
2017
39
Lymph node tuberculosis mimicking malignancy on (18)F-FDG PET/CT in two patients: A case report. ( 28587415 )
2017
40
The reliability of rifampicin resistance as a proxy for multidrug-resistant tuberculosis: a systematic review of studies from Iran. ( 28823010 )
2017
41
Post-tuberculosis mycetoma: bronchoscopic removal. ( 28580148 )
2017
42
Abdominal tuberculosis after removal of an adjustable gastric band - report of an unusual case. ( 28694906 )
2017
43
Ruptured Pulmonary Cystic Echinococcosis Mimicking Tuberculosis in Childhood: A Case Report. ( 28695838 )
2017
44
Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science. ( 28845791 )
2017
45
A Rare Case of Primary Calcific Pleural Tuberculosis - A Case Report. ( 28892960 )
2017
46
Who are the patients that default tuberculosis treatment? - space matters! ( 28091336 )
2017
47
Multifocal Tubercular Dactylitis: A Rare Presentation of Skeletal Tuberculosis in an Adult. ( 28764233 )
2017
48
The predominance of Ethiopian specific Mycobacterium tuberculosis families and minimal contribution of Mycobacterium bovis in tuberculous lymphadenitis patients in Southwest Ethiopia. ( 28919549 )
2017
49
Mannose-binding lectin (MBL) deficiency and tuberculosis infection in patients with ankylosing spondylitis. ( 28879439 )
2017
50
Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). ( 28953378 )
2017

Variations for Tuberculosis

Expression for Tuberculosis

Search GEO for disease gene expression data for Tuberculosis.

Pathways for Tuberculosis